Cargando…

Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions

Purpose: To investigate the penetration of 0.3% gatifloxacin ophthalmic gel, 0.3% gatifloxacin ophthalmic solution and 0.5% levofloxacin ophthalmic solution into aqueous humor after topical application. Materials and Methods: Age-related cataract patients (150 eyes in 150 cases) receiving phacoemuls...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Wenting, Ni, Weiling, Chen, Huilian, Yuan, Jingqun, Huang, Xiaodan, Zhang, Zheng, Wang, Yao, Yu, Yibo, Yao, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466517/ https://www.ncbi.nlm.nih.gov/pubmed/26078713 http://dx.doi.org/10.7150/ijms.11376

Ejemplares similares

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Comparative Study of Ocular Pharmacokinetics of Topical 0.3% Gatifloxacin Eye Gel and Solution in Rabbits
por: Liu, Manli, et al.
Publicado: (2022)

Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyes
por: Silva, G.C.M., et al.
Publicado: (2017)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis
por: Cervantes, Lorenzo J, et al.
Publicado: (2011)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
por: Deom, James E, et al.
Publicado: (2022)

Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis: Safety, Efficacy and Patient Perspective
por: Schultz, Clyde
Publicado: (2012)

Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin
por: Sugioka, Koji, et al.
Publicado: (2009)

Post-Marketing Surveillance of Levofloxacin 0.5% Ophthalmic Solution for External Ocular Infections
por: Kanda, Yoshiko, et al.
Publicado: (2012)

Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis
por: Mah, Francis S., et al.
Publicado: (2021)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose
por: Silverstein, Steven M.
Publicado: (2019)

LiNi(0.4)Co(0.3)Mn(0.3)O(2 )thin film electrode by aerosol deposition
por: Kim, Icpyo, et al.
Publicado: (2012)

Dielectric Tunability Properties in (110)-Oriented Epitaxial 0.5Ba(Ti(0.8)Zr(0.2))O(3)-0.5(Ba(0.7)Ca(0.3))TiO(3) Thin Films Prepared by PLD Method
por: Luo, Bing, et al.
Publicado: (2020)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

Anisotropic Properties of Epitaxial Ferroelectric Lead-Free 0.5[Ba(Ti(0.8)Zr(0.2))O(3)]-0.5(Ba(0.7)Ca(0.3))TiO(3) Films
por: Cucciniello, Nicholas, et al.
Publicado: (2023)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Gheith, Moataz E, et al.
Publicado: (2008)

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye
por: Park, Yuli, et al.
Publicado: (2017)

Adapalene 0.3% Gel Shows Efficacy for the Treatment of Atrophic Acne Scars
por: Loss, Manisha J., et al.
Publicado: (2018)

Efficacy of Gatifloxacin in Acute Bacterial Corneal ulcer
por: Afzal Junejo, Sameen, et al.
Publicado: (2013)

Effect of Poling on Multicatalytic Performance of 0.5Ba(Zr(0.2)Ti(0.8))O(3)-0.5(Ba(0.7)Sr(0.3))TiO(3) Ferroelectric Ceramic for Dye Degradation
por: Gaur, Akshay, et al.
Publicado: (2022)

Influence of Grain Size on Dielectric Behavior in Lead-Free 0.5 Ba(Zr(0.2)Ti(0.8))O(3)–0.5 (Ba(0.7)Ca(0.3))TiO(3) Ceramics
por: Ene, Vladimir Lucian, et al.
Publicado: (2023)

Manipulating magnetoelectric properties by interfacial coupling in La(0.3)Sr(0.7)MnO(3)/Ba(0.7)Sr(0.3)TiO(3) superlattices
por: Guo, Haizhong, et al.
Publicado: (2017)

Comparative Investigation of 0.5Li(2)MnO(3)·0.5LiNi(0.5)Co(0.2)Mn(0.3)O(2) Cathode Materials Synthesized by Using Different Lithium Sources
por: Wang, Peng-Bo, et al.
Publicado: (2018)

Magnetocapacitance in La(0.7)Sr(0.3)MnO(3)/Pb(Zr(0.2)Ti(0.8))O(3)/La(0.7)Sr(0.3)MnO(3) multiferroic heterostructures
por: Hrib, Luminita M., et al.
Publicado: (2017)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober, Dietmar, et al.
Publicado: (2015)

Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach
por: Pienaar, Elsje, et al.
Publicado: (2017)

Experimental and Theoretical Studies of Hydrogen Storage in LaNi(4.4)Al(0.3)Fe(0.3) Hydride Bed
por: Briki, Chaker, et al.
Publicado: (2023)

Anomalous behavior above the Curie temperature in (Nd(1−x)Gd(x))(0.55)Sr(0.45)MnO(3) (x = 0, 0.1, 0.3 and 0.5)
por: Kamel, R., et al.
Publicado: (2019)

Rosen-Type Piezoelectric Transformers Based on 0.5Ba(Zr(0.2)Ti(0.8))O(3)–0.5(Ba(0.7)Ca(0.3))TiO(3) Ceramic and Doped with Sb(2)O(3)
por: Jung, Suk-Young, et al.
Publicado: (2023)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

Structural, optical, electric and dielectric characterization of a NaCu(0.2)Fe(0.3)Mn(0.5)O(2) compound
por: Ben Slima, Ichrak, et al.
Publicado: (2022)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin, Joan-En, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_je2hug31k5jmdkmuk9k9kimnh0